Get access

Is interleukin-27 a real candidate for immunotherapies of multiple sclerosis?



Yoh Matsumoto MD, PhD, Department of Immunotherapy Development, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.

Tel: +81-3-6834-2377

Fax: +81-3-5316-3222



As interleukin (IL)-27 has immunosuppressive effects and blocks Th17 differentiation, some researchers have investigated the possibility of the use of IL-27 for treatment of autoimmune diseases including multiple sclerosis. However, it has now been shown that the functions of IL-27 are more pleomorphic than expected. Therefore, more detailed analysis is necessary before entering this phase.

Get access to the full text of this article